CBU
SUPN icon

CIBC Bancorp USA’s Supernus Pharmaceuticals SUPN Stock Holding History

CIBC Bancorp USA’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$275K Buy
+5,751
New +$232K ﹤0.01% 1126

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's SUPN Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Supernus Pharmaceuticals (SUPN) in Q3 2025: 5,751 shares worth $275K. The stake represents ﹤0.01% of the portfolio and ranks #1126 among its holdings.

310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • CIBC Bancorp USA held 5,751 shares of Supernus Pharmaceuticals worth $275K as of Q3 2025.
  • Supernus Pharmaceuticals was a new CIBC Bancorp USA position in Q3 2025.
  • Supernus Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1126 holding.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.